2005年至2010年日本类风湿性关节炎患者带状疱疹的发病率。

Incidence of herpes zoster in Japanese patients with rheumatoid arthritis from 2005 to 2010.

作者信息

Nakajima Ayako, Urano Wako, Inoue Eisuke, Taniguchi Atsuo, Momohara Shigeki, Yamanaka Hisashi

机构信息

Institute of Rheumatology, Tokyo Women's Medical University , Shinjuku-ku, Tokyo , Japan.

出版信息

Mod Rheumatol. 2015 Jul;25(4):558-61. doi: 10.3109/14397595.2014.984829. Epub 2015 Feb 4.

DOI:10.3109/14397595.2014.984829

PMID:25648973

Abstract

OBJECTIVE

To clarify the incidence and the risks of herpes zoster infection in Japanese patients with rheumatoid arthritis (RA).

METHODS

By using a self-report of occurrence of herpes zoster in patients with RA in a large observational cohort study from 2005 to 2010, the standardized incidence rate was calculated. A Cox model was used to analyze risk factors for occurrence of herpes zoster.

RESULTS

A total of 7,986 patients (female 83.1%) accumulated 30,140 patient-years of observation, and 366 events were confirmed. The standardized incidence rate per 1,000 patient-years was 9.1 (95% confidence interval (CI) 6.2-12.9) in total, 7.8 (3.6-14.8) in men, and 10.3 (6.8-15.0) in women. The risk factors for herpes zoster were age [/10 years: Hazard ratio (HR) 1.268, 95% CI 1.153-1.393, p < 0.0001), high disease activity compared with remission (HR 1.642, 95% CI 1.067-2.528, p < 0.05), prednisolone (< 5 mg/day compared with 0 mg/day: HR 1.531, 95% CI 1.211-1.936, p < 0.001; ≥ 5 mg/day compared with 0 mg/day: HR 1.471, 95% CI 1.034-2.093, p < 0.05), and methotrexate (HR 1.382, 95% CI 1.076-1.774, p < 0.05).

CONCLUSION

This study quantified the historical incidence and risk for herpes zoster in Japanese RA patients, and is a benchmark for future studies.

摘要

目的

明确日本类风湿关节炎（RA）患者带状疱疹感染的发病率及风险。

方法

在一项2005年至2010年的大型观察性队列研究中，通过类风湿关节炎患者带状疱疹发生情况的自我报告，计算标准化发病率。采用Cox模型分析带状疱疹发生的危险因素。

结果

总共7986例患者（女性占83.1%）累计观察30140患者年，确诊366例事件。每1000患者年的标准化发病率总计为9.1（95%置信区间[CI]6.2 - 12.9），男性为7.8（3.6 - 14.8），女性为10.3（6.8 - 15.0）。带状疱疹的危险因素包括年龄[每增加10岁：风险比（HR）1.268，95%CI 1.153 - 1.393，p < 0.0001]、与缓解期相比疾病活动度高（HR 1.642，95%CI 1.067 - 2.528，p < 0.05）、泼尼松龙（<5mg/天与0mg/天相比：HR 1.531，95%CI 1.211 - 1.936，p < 0.001；≥5mg/天与0mg/天相比：HR 1.471，95%CI 1.034 - 2.093，p < 0.05）以及甲氨蝶呤（HR 1.382，95%CI 1.076 - 1.774，p < 0.05）。